Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech AB (ATVBF) issued an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis, or RRMS.
The companies are to initiate a third Phase III study of laquinimod, following the written agreement reached with the U.S. Food and Drug Administration, or FDA, on the Special Protocol Assessment.
The third Phase III laquinimod trial CONCERTO will assess two doses of the investigational product (0.6mg and 1.2mg) in around 1,800 patients for up to 24 months. The primary outcome measure will be confirmed disability progression as measured by the Expanded Disability Status Scale.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.